FAQs
What is Irinotecan?
- Irinotecan solution is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy
- It is the first topoisomerase I inhibitor approved for this purpose
- Topoisomerases are nuclear enzymes that prepare DNA for replication. Topoisomerase inhibitors appear to act by binding to DNA-topoisomerase complexes, leading to DNA damage when replication enzymes collide with the drug-enzyme DNA complex
In this section
Disclaimer
The products may not be available for sale, may not be registered, approved or cleared for use as claimed, in all countries where Biocompatibles is represented.